Amneal launches 4 generics

Amneal is expanding its portfolio of generic products. The company is introducing four new generics:

• Vasopressin injection 1 ml, which is a generic of the antidiuretic hormone Vasostrict. Vasopressin had a market value of $624 million, according to June 2022 IQVIA data;
• Famotidine for oral suspension (40 mg/5 ml), an H2 antagonist, which is a generic of Pepcid. The product had a market value of $96 million, according to June 2022 IQVIA data;
• Atropine sulfate 1% ophthalmic solution, an anticholinergic, which is a generic of Atropine sulfate ophthalmic solution. The medication had a market value of $35 million, according to June 2022 IQVIA data; and
• Clindamycin phosphate topical gel, 1% (75 ml), which is a generic of Clindagel. This product received Competitive Generic Therapy approval designation. The product had a market value of $29 million, according to June 2022 IQVIA data.

[Read more: Amneal debuts 2 generics] 

“We are pleased to add these four new products to our essential medicines portfolio,” co-CEOs Chirag and Chintu Patel said. “Most notably, vasopressin expands our injectables portfolio and drives further scale in that business for us. Each year, we target 20 to 30 new product launches in generics, and we are on track to achieving that goal again in 2022.”

[Read more: Amneal receives FDA blessing for 4 generics]